Bradykinin Receptor B1 (BDKRB1) Antibody

Product specifications

Primary Antibodies

Bradykinin Receptor B1 (BDKRB1)

Rabbit

Human

ELISA: 1/5000, WB: 1/500 - 1/2000, IF/ICC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

IgG

Purified by affinity chromatography.

50 µg

100 µg

Liquid

ELISA, WB, IF/ICC

PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Shipped within 5-10 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

P46663

623

BDKRB1,B1BKR,BKR1,B1R,bradykinin receptor,BKB1R,BRADYB1

Antibody anti-BDKRB1

RUO

Descripción

Bradykinin Receptor B1 (BDKRB1) is an inducible GPCR primarily expressed during inflammatory responses and tissue injury. Unlike the constitutively expressed B2 receptor, B1 is induced by pro-inflammatory cytokines, such as IL-1β and TNF-α, in response to chronic inflammation, trauma, or infection. BDKRB1 binds des-Arg9-bradykinin, a bradykinin metabolite, and mediates pro-inflammatory effects, including pain sensitization, vasodilation, and vascular permeability. This receptor plays a pivotal role in chronic pain conditions, such as neuropathic pain and inflammatory hyperalgesia, by sensitizing sensory neurons and enhancing pain signaling. BDKRB1 also contributes to angiogenesis and leukocyte recruitment, facilitating immune responses during infection and injury. In the cardiovascular system, B1 activation is associated with hypertension, vascular remodeling, and endothelial dysfunction. Dysregulation of BDKRB1 signaling is linked to conditions like diabetic complications, chronic inflammatory diseases, and certain cancers, where it can promote tumor growth and metastasis. Targeting BDKRB1 with antagonists has shown promise in preclinical models for managing chronic pain, inflammation, and vascular disorders, making it an emerging target for therapeutic development.

Related Products

B1 Bradykinin Receptor (BDKRB1) Antibody

Bradykinin, a 9 aa peptide, is generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. Two types of G-protein coupled receptors have been found which bind bradykinin and mediate responses to these pathophysiologic conditions. BDKRB1 is one of these receptors and is synthesized de novo following tissue injury. Receptor binding leads to an increase in the cytosolic calcium ion concentration, ultimately resulting in chronic and acute inflammatory responses.

Ver Producto

Bradykinin Receptor B1 (BDKRB1) Antibody

BDKRB1 Antibody is a Rabbit Polyclonal against BDKRB1.

Ver Producto

Bradykinin Receptor B1 (BDKRB1) Antibody

Bradykinin receptor B1 Antibody is a Goat Polyclonal antibody against Bradykinin receptor B1.

Ver Producto